These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 21474491)

  • 21. P2Y
    Al-Najjar BO; Saqallah FG; Abbas MA; Al-Hijazeen SZ; Sibai OA
    Eur J Med Chem; 2022 Jan; 227():113924. PubMed ID: 34731765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): in vitro effects on platelets.
    Bryant J; Post JM; Alexander S; Wang YX; Kent L; Schirm S; Tseng JL; Subramanyam B; Buckman B; Islam I; Yuan S; Sullivan ME; Snider M; Morser J
    Thromb Res; 2008; 122(4):523-32. PubMed ID: 18495218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function.
    Iyú D; Glenn JR; White AE; Fox SC; van Giezen H; Nylander S; Heptinstall S
    Thromb Haemost; 2011 Jan; 105(1):96-106. PubMed ID: 20941457
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ticagrelor: from discovery to Phase III clinical trial.
    Siller-Matula JM; Jilma B
    Future Cardiol; 2010 Nov; 6(6):753-64. PubMed ID: 21142630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional profile of the platelet P2Y₁₂ receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease.
    Ueno M; Ferreiro JL; Tomasello SD; Capodanno D; Tello-Montoliu A; Kodali M; Seecheran N; Dharmashankar K; Alissa R; Capranzano P; Desai B; Charlton RK; Bass TA; Angiolillo DJ
    Thromb Haemost; 2011 Apr; 105(4):730-2. PubMed ID: 21225097
    [No Abstract]   [Full Text] [Related]  

  • 26. Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate.
    Cattaneo M
    Thromb Haemost; 2011 May; 105 Suppl 1():S67-74. PubMed ID: 21479342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis, structure-property relationships and pharmacokinetic evaluation of ethyl 6-aminonicotinate sulfonylureas as antagonists of the P2Y₁₂ receptor.
    Bach P; Boström J; Brickmann K; van Giezen JJ; Groneberg RD; Harvey DM; O'Sullivan M; Zetterberg F
    Eur J Med Chem; 2013 Jul; 65():360-75. PubMed ID: 23747805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. P2Y
    Mansour A; Bachelot-Loza C; Nesseler N; Gaussem P; Gouin-Thibault I
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32092903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resistance to anti-platelet agents.
    Cattaneo M
    Thromb Res; 2011 Feb; 127 Suppl 3():S61-3. PubMed ID: 21262444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of antiplatelet therapy in the secondary prevention of coronary artery disease.
    Behan MW; Chew DP; Aylward PE
    Curr Opin Cardiol; 2010 Jul; 25(4):321-8. PubMed ID: 20386440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information.
    Paoletta S; Sabbadin D; von Kügelgen I; Hinz S; Katritch V; Hoffmann K; Abdelrahman A; Straßburger J; Baqi Y; Zhao Q; Stevens RC; Moro S; Müller CE; Jacobson KA
    J Comput Aided Mol Des; 2015 Aug; 29(8):737-56. PubMed ID: 26194851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aspirin, P2Y12 blockers, cilostazol, PAR-1 blockers and emerging antiplatelet therapies: can biomarkers guide clinical development and practice?
    Menown IB
    Biomark Med; 2011 Feb; 5(1):1-3. PubMed ID: 21319960
    [No Abstract]   [Full Text] [Related]  

  • 33. IKKbeta inhibitors identification part I: homology model assisted structure based virtual screening.
    Nagarajan S; Doddareddy Mr; Choo H; Cho YS; Oh KS; Lee BH; Pae AN
    Bioorg Med Chem; 2009 Apr; 17(7):2759-66. PubMed ID: 19285872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of endogenous surrogate ligands for human P2Y12 receptors by in silico and in vitro methods.
    Nonaka Y; Hiramoto T; Fujita N
    Biochem Biophys Res Commun; 2005 Nov; 337(1):281-8. PubMed ID: 16185654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GPCR structure-based virtual screening approach for CB2 antagonist search.
    Chen JZ; Wang J; Xie XQ
    J Chem Inf Model; 2007; 47(4):1626-37. PubMed ID: 17580929
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integration of virtual screening with high-throughput flow cytometry to identify novel small molecule formylpeptide receptor antagonists.
    Edwards BS; Bologa C; Young SM; Balakin KV; Prossnitz ER; Savchuck NP; Sklar LA; Oprea TI
    Mol Pharmacol; 2005 Nov; 68(5):1301-10. PubMed ID: 16118363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
    Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
    J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel series of piperazinyl-pyridine ureas as antagonists of the purinergic P2Y12 receptor.
    Bach P; Boström J; Brickmann K; van Giezen JJ; Hovland R; Petersson AU; Ray A; Zetterberg F
    Bioorg Med Chem Lett; 2011 May; 21(10):2877-81. PubMed ID: 21507636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Homology modeling and docking evaluation of aminergic G protein-coupled receptors.
    McRobb FM; Capuano B; Crosby IT; Chalmers DK; Yuriev E
    J Chem Inf Model; 2010 Apr; 50(4):626-37. PubMed ID: 20187660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antagonism of P2Y₁₂ reduces physiological thromboxane levels.
    Bhavaraju K; Georgakis A; Jin J; Gartner TK; Tomiyama Y; Nurden A; Nurden P; Kunapuli SP
    Platelets; 2010; 21(8):604-9. PubMed ID: 21067313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.